SOPHiA GENETICS SA (SOPH) CTO details options and RSU-based stake

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma filed an initial Form 3 reporting his equity holdings in the company. He directly holds 125,813 ordinary shares, which include 80,762 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time through dates extending to April 2, 2028.

Verma also holds several share options over ordinary shares: 31,847 at an exercise price of $8.36 expiring March 30, 2032, 130,112 at $4.72 expiring April 3, 2033, 182,927 at $4.96 expiring April 2, 2034, and 136,364 at $3.29 expiring April 2, 2035. These options vest in stages, with portions becoming exercisable on specific dates and the remainder vesting in equal monthly installments through 2027.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Verma Abhimanyu

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	125,813(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	03/30/2032	Ordinary Shares	31,847	$8.36	D
Share Option (Right to Buy)	(3)	04/03/2033	Ordinary Shares	130,112	$4.72	D
Share Option (Right to Buy)	(4)	04/02/2034	Ordinary Shares	182,927	$4.96	D
Share Option (Right to Buy)	(5)	04/02/2035	Ordinary Shares	136,364	$3.29	D

Explanation of Responses:

1. Includes 80,762 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 122 ordinary shares from a March 30, 2022 grant vesting in equal monthly installments through March 30, 2026; (ii) 26,484 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 23,292 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 30,864 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.

2. The share option vests and becomes exercisable as to 25% of the ordinary shares on March 30, 2023, and then in equal monthly installments through March 30, 2026.

3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.

4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.

5. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in-fact for Abhimanyu Verma	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does SOPHiA GENETICS SA (SOPH) CTO Abhimanyu Verma report on this Form 3?

Abhimanyu Verma reports his initial ownership of SOPHiA GENETICS SA equity. He directly holds 125,813 ordinary shares and multiple share option grants over additional ordinary shares, providing transparency into his total equity-based stake as Chief Technology Officer.

How many SOPHiA GENETICS SA ordinary shares does the CTO directly own on this Form 3?

The CTO directly owns 125,813 ordinary shares of SOPHiA GENETICS SA. This figure includes shares already issued plus 80,762 ordinary shares that will be delivered upon settlement of restricted stock units, subject to continued service and vesting schedules.

What share options are reported by the SOPHiA GENETICS SA CTO on this Form 3?

The CTO reports several share options over ordinary shares: 31,847 at $8.36, 130,112 at $4.72, 182,927 at $4.96, and 136,364 at $3.29. These options expire between March 2032 and April 2035 and vest over multi-year schedules.

How do the restricted stock units (RSUs) for SOPHiA GENETICS SA’s CTO vest?

The 80,762 RSU-linked ordinary shares vest over several years. Four grants vest in monthly or quarterly installments, with final vesting dates running through April 2, 2028, and one grant vesting 50% on April 2, 2026, then quarterly through April 2, 2027.

Does this SOPHiA GENETICS SA Form 3 show any insider buying or selling by the CTO?

This Form 3 lists existing holdings rather than new trades. It reports the CTO’s current ordinary share position and outstanding options and RSUs, but does not show open-market purchases or sales because it is an initial beneficial ownership statement.

What are the key expiration dates for SOPHiA GENETICS SA CTO share options?

The share options expire on four future dates: March 30, 2032; April 3, 2033; April 2, 2034; and April 2, 2035. Each option grant must be vested and exercised before its respective expiration date to convert into ordinary shares.